Cite

Copy

Tap on and choose 'Add to Home Screen' to create a shortcut app

Tap on and choose 'Add to Home Screen/Install App' to create a shortcut app

On The Horizon for Chemotherapy for Tumors in the Nervous System of Children

This page was last updated on May 9th, 2017

  • Stratification of therapy according to molecular profile: It is likely that Wnt signaling pathway medulloblastomas will require less radiation than the current standard (34); desmoplastic medulloblastomas may be cured with chemotherapy alone (29).
  • Signaling pathway inhibitors: These have been disappointing up to now; however, they may have a role in conjunction with chemotherapy in the future (28).
  • Personalized chemotherapy based on molecular behavior: The potential to personalize treatment according to the response of growing individual tumors in vitro may be a previously untapped possibility for aggressive tumors in the future (48).
  • Immunotherapy: This is currently being explored in clinical trials; this approach has been disappointing up to now (47).
  • Antiangiogenesis therapy: This approach is continuing to be evaluated (5).
  • Histone deacetylase inhibitors: These agents are currently in phase II clinical trials; their value remains to be determined (49).

Your donations keep us going

The ISPN Guide is free to use, but we rely on donations to fund our ongoing work and to maintain more than a thousand pages of information created to disseminate the most up-to-date knowledge in the field of paediatric neurosurgery.

By making a donation to The ISPN Guide you are also indirectly helping the many thousands of children around the world whose treatment depends on well-informed surgeons.

Please consider making a donation today.

Use the app

The ISPN Guide can be used as a standalone app, both on mobile devices and desktop computers. It’s quick and easy to use.

Fully featured

Free registration grants you full access to The Guide and host of featured designed to help further your own education.

Stay updated

The ISPN Guide continues to expand both in breadth and depth. Join our mailing list to stay up-to-date with our progress.